Medline (NASDAQ:MDLN) Stock Has Consensus Target Price of $46.08

Shares of Medline (NASDAQ:MDLN) have been assigned an average rating of “Moderate Buy” from the twenty-nine analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and twenty-three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $46.08.

Several brokerages have recently weighed in on MDLN. Wall Street Zen upgraded Medline from a “hold” rating to a “buy” rating in a research report on Saturday. Mizuho decreased their price target on shares of Medline from $48.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. Robert W. Baird set a $42.00 price objective on Medline in a report on Thursday, August 6th. Stifel Nicolaus lowered their price target on shares of Medline from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings cut shares of Medline from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th.

Insider Activity

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares in the company, valued at $715,182,924.05. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 7,948,676 shares of company stock valued at $281,805,137. 0.81% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Medline

Several hedge funds have recently bought and sold shares of MDLN. GAMMA Investing LLC grew its stake in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after acquiring an additional 254 shares during the last quarter. Covestor Ltd boosted its stake in shares of Medline by 31.8% during the 3rd quarter. Covestor Ltd now owns 1,953 shares of the company’s stock worth $68,000 after acquiring an additional 471 shares during the last quarter. NewEdge Advisors LLC grew its stake in shares of Medline by 100.0% during the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 475 shares during the period. Allworth Financial LP increased its stake in shares of Medline by 86.2% in the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after purchasing an additional 487 shares in the last quarter. Finally, Whipplewood Advisors LLC purchased a new stake in Medline in the 1st quarter worth $30,000.

Medline Stock Performance

NASDAQ:MDLN opened at $39.64 on Friday. The business’s fifty day moving average is $34.78 and its 200 day moving average is $39.48. The firm has a market cap of $52.12 billion and a price-to-earnings ratio of 90.09. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.61 and a current ratio of 4.04. Medline has a 52-week low of $31.37 and a 52-week high of $50.88.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.21% and a net margin of 1.84%. Research analysts predict that Medline will post 1.50 EPS for the current year.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. Shares gapped higher following the earnings report. Medline shares gap up following strong earnings
• Positive Sentiment: Analyst target increases add to the bullish outlook: UBS raised its target to $49 and maintained a Buy rating; Citi raised its target to $47 and kept Buy; and Leerink Partners lifted its target to $46 with an Outperform rating. UBS ratings Citi ratings Leerink Partners ratings
• Positive Sentiment: BTIG reaffirmed its Buy rating with a $55 target, while Barclays also assigned a Buy rating, adding to the favorable analyst sentiment. BTIG ratings Barclays rating
• Positive Sentiment: Medline plans price increases in 2027 to offset inflation, which could help protect revenue and profitability if customers accept the higher prices. Pricing plans and Q3 results

About Medline

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.